Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Sun Joo Cha, Kiyoung Kim
Formato:	Artigo
Idioma:	English
Publicado em:	MDPI AG 2022-01-01
coleção:	Antioxidants
Assuntos:	edaravone oxidative stress antioxidant mitochondria neurodegenerative disease amyotrophic lateral sclerosis
Acesso em linha:	https://www.mdpi.com/2076-3921/11/2/195

Registros relacionados

A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
por: Erdi Şahin
Publicado em: (2018-03-01)

Edaravone: A new hope for patients with amyotrophic lateral sclerosis
por: Shivangi Garg, et al.
Publicado em: (2019-01-01)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Hideki Houzen, et al.
Publicado em: (2021-07-01)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Jin-Mo Park, et al.
Publicado em: (2022-07-01)

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
por: Chang Liu, et al.
Publicado em: (2024-10-01)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Hee Jo Han, et al.
Publicado em: (2022-12-01)

New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments
por: Maria A. Lapshina, et al.
Publicado em: (2023-11-01)

Bulbar Onset Amyotrophic Lateral Sclerosis: A Case Report
por: Kabindra Rai, et al.
Publicado em: (2023-02-01)

The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
por: Jiantao Zhao, et al.
Publicado em: (2022-06-01)

Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
por: Hyun-Jun Choi, et al.
Publicado em: (2020-09-01)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
por: Benjamin Rix Brooks, et al.
Publicado em: (2022-10-01)

Iranian clinical practice guideline for amyotrophic lateral sclerosis
por: Reza Boostani, et al.
Publicado em: (2023-06-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
por: Kamila Tuzim, et al.
Publicado em: (2018-08-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
por: Kamila Tuzim, et al.
Publicado em: (2018-08-01)

The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing
por: Aki Soejima-Kusunoki, et al.
Publicado em: (2022-07-01)

Amyotrophic lateral sclerosis with frontotemporal dementia
por: Corina Roman-Filip, et al.
Publicado em: (2010-09-01)

Synthesis and Characterization of Edaravone Analogues as Remyelinating Agents and Putative Mechanistic Probes
por: Eleonora Colombo, et al.
Publicado em: (2023-10-01)

Advancements and challenges in amyotrophic lateral sclerosis
por: David Bradford, et al.
Publicado em: (2024-05-01)

Intestinal Microbiota and Sclerosis Lateral Amyotrophic
por: Mariana Dantas de Carvalho Vilar, et al.
Publicado em: (2022-03-01)

The implications of DNA methylation for amyotrophic lateral sclerosis
por: ADRIANA HELENA DE OLIVEIRA REIS, et al.
Publicado em: (2023-10-01)

The role of statins in amyotrophic lateral sclerosis: protective or not?
por: Hayder M. Al-kuraishy, et al.
Publicado em: (2024-06-01)

Evaluation of Sensory Nerve Conduction Abnormalities in Patients with Amyotrophic Lateral Sclerosis
por: Waseem H. Alkhaffaf
Publicado em: (2021-06-01)

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis
por: Frances Theunissen, et al.
Publicado em: (2021-11-01)

Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704
por: Dong Wook Kang, et al.
Publicado em: (2021-09-01)

Prevalence of amyotrophic lateral sclerosis in Latium region, Italy
por: Maria Puopolo, et al.
Publicado em: (2021-12-01)

Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship
por: Niccolò Candelise, et al.
Publicado em: (2022-03-01)

Progress in the study of mitochondrial dysfunction in pathogenesis of amyotrophic lateral sclerosis
por: LIU Liyang, LIU Qing, LIU Yaping, ZHANG Xue
Publicado em: (2023-02-01)

Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
por: T. M. Alekseeva, et al.
Publicado em: (2019-01-01)

Commentary: Urinary Neopterin, a New Marker of the Neuroinflammatory Status in Amyotrophic Lateral Sclerosis
por: Gisele Espíndola, et al.
Publicado em: (2021-03-01)

Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients
por: Swapnil Samadhiya, et al.
Publicado em: (2022-01-01)

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage
por: Marguerite Jamet, et al.
Publicado em: (2024-03-01)

Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols
por: Anne Vejux, et al.
Publicado em: (2018-01-01)

The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis
por: Christoph Schweingruber, et al.
Publicado em: (2022-08-01)

Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis
por: Mengli Wang, et al.
Publicado em: (2021-06-01)

Depression in amyotrophic lateral sclerosis
por: Joanna Iłżecka
Publicado em: (2021-10-01)

Amyotrophic lateral sclerosis : advances and perspectives of neuronanomedicine /
por: Machtoub, Lina, author, et al.
Publicado em: (2016)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: HaEun Cho, et al.
Publicado em: (2020-12-01)

Staging model for amyotrophic lateral sclerosis in Singapore
por: Yuan Teck Tay, et al.
Publicado em: (2022-07-01)

Analysis of SOD1 and C9orf72 mutations in patients with amyotrophic lateral sclerosis in Antioquia, Colombia
por: Jimena Jaramillo, et al.
Publicado em: (2022-12-01)

Pain in Amyotrophic Lateral Sclerosis Is Underrated
por: Soyoung Kwak, et al.
Publicado em: (2024-12-01)